Literature DB >> 8705856

Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells.

H Hanenberg1, X L Xiao, D Dilloo, K Hashino, I Kato, D A Williams.   

Abstract

Hematopoietic cells are important targets for genetic modification with retroviral vectors. Attempts at human gene therapy of stem cells have achieved limited success partly because of low gene transfer efficiency. Chymotryptic fragments of the extracellular matrix molecule fibronectin used during infection have been shown to increase transduction of human hematopoietic progenitor cells. Here, we demonstrate that this enhanced gene transfer into mammalian target cells is due to direct binding of retroviral particles to sequences within the fibronectin molecule. Transduction of mammalian cells, including murine long-term repopulating hematopoietic cells, is greatly enhanced when cells are adherent to chimeric fragments containing these retroviral binding sequences. In addition, colocalization of retrovirus and target cells on fibronectin peptides allows targeted transduction of specific cell types by exploiting unique ligand/receptor interactions.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8705856     DOI: 10.1038/nm0896-876

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  106 in total

Review 1.  Gene therapy for the hemoglobin disorders: past, present, and future.

Authors:  D A Persons; A W Nienhuis
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-09       Impact factor: 11.205

2.  Dual HLA class I and class II restricted recognition of alloreactive T lymphocytes mediated by a single T cell receptor complex.

Authors:  M H Heemskerk; R A de Paus; E G Lurvink; F Koning; A Mulder; R Willemze; J J van Rood; J H Falkenburg
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-29       Impact factor: 11.205

Review 3.  Gene-marking studies of hematopoietic cells.

Authors:  C M Bollard; H E Heslop; M K Brenner
Journal:  Int J Hematol       Date:  2001-01       Impact factor: 2.490

Review 4.  Hematopoietic stem cell gene therapy.

Authors:  David W Emery; Tamon Nishino; Ken Murata; Michalis Fragkos; George Stamatoyannopoulos
Journal:  Int J Hematol       Date:  2002-04       Impact factor: 2.490

5.  Disruption of alpha beta but not of gamma delta T cell development by overexpression of the helix-loop-helix protein Id3 in committed T cell progenitors.

Authors:  B Blom; M H Heemskerk; M C Verschuren; J J van Dongen; A P Stegmann; A Q Bakker; F Couwenberg; P C Res; H Spits
Journal:  EMBO J       Date:  1999-05-17       Impact factor: 11.598

Review 6.  Selective expansion of transduced cells for hematopoietic stem cell gene therapy.

Authors:  Akihiro Kume; Yutaka Hanazono; Hiroaki Mizukami; Takashi Okada; Keiya Ozawa
Journal:  Int J Hematol       Date:  2002-11       Impact factor: 2.490

7.  A self-inactivating lentiviral vector for SCID-X1 gene therapy that does not activate LMO2 expression in human T cells.

Authors:  Sheng Zhou; Disha Mody; Suk See DeRavin; Julia Hauer; Taihe Lu; Zhijun Ma; Salima Hacein-Bey Abina; John T Gray; Michael R Greene; Marina Cavazzana-Calvo; Harry L Malech; Brian P Sorrentino
Journal:  Blood       Date:  2010-05-10       Impact factor: 22.113

8.  Scaffold-Mediated Static Transduction of T Cells for CAR-T Cell Therapy.

Authors:  Pritha Agarwalla; Edikan A Ogunnaike; Sarah Ahn; Frances S Ligler; Gianpietro Dotti; Yevgeny Brudno
Journal:  Adv Healthc Mater       Date:  2020-06-11       Impact factor: 9.933

Review 9.  Gene therapy of X-linked severe combined immunodeficiency.

Authors:  Salima Hacein-Bey-Abina; Alain Fischer; Marina Cavazzana-Calvo
Journal:  Int J Hematol       Date:  2002-11       Impact factor: 2.490

10.  Retrovirus-associated heparan sulfate mediates immobilization and gene transfer on recombinant fibronectin.

Authors:  Pedro Lei; Bharat Bajaj; Stelios T Andreadis
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.